| Product Unit Size | Cost | Quantity | Stock |
|---|
NU-2058 is a guanine-based cyclin-dependent kinase (CDK) inhibitor with selectivity for CDK1/2. In androgen-independent prostate cancer, NU-2058 shows efficacy in bicalutamide-resistant cells. It also inhibits the proliferation of breast cancer cells lines regardless of genetic background or sensitivity to anti-estrogens. NU-2058 and other CDK1/2 inhibitors are a possible therapeutic path for endocrine-resistant breast cancer.
| Cas No. | 161058-83-9 |
|---|---|
| Purity | ≥98% |
| Formula | C12H17N5O |
| Formula Wt. | 247.30 |
| IUPAC Name | 6-(Cyclohexylmethoxy)-3H-purin-2-amine |
| Synonym | NU2058, O6-Cyclohexylmethylguanine |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Rigas, A., Robson, C., et al. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene. 26(55): 7611-7619 (2007). PMID 17599054.
Johnson N., Bentley J., et al. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. Br J Cancer. 102(2):342-350 (2010). PMID: 20010939.